This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

BAUS 2024: Imaging and nmCRPC

The big debate

NUBEQA® (darolutamide)

At the BAUS Annual Conference 2024, Professor Alison Birtle and Mr. Bill Cross participated in a live discussion focused on imaging and treatment options for patients with nmCRPC. 

 

In this session, you will discover:  

• Next-generation imaging – what are the guidelines and how do they influence treatment decisions? 

• Clinical and real-world data supporting NUBEQA + ADT in high-risk nmCRPC patients: enhancing overall survival while preserving quality of life. 

 

This symposium was organised and funded by Bayer plc.

NUBEQA Prescribing Information

Speakers

BAUS 2024: Urology and Oncology in Partnership
NUBEQA® (darolutamide)
PP-NUB-GB-2080, January 2025
BAUS 2024: Management of CV toxicity and bone health
NUBEQA® (darolutamide)
PP-NUB-GB-2079, January 2025

PP-NUB-GB-2081 | January 2025